Carpal tunnel syndrome is the most common compressive neuropathy of the upper limb and the most frequently performed elective hand operation. The condition has been written about for more than a century, and yet the 2024 / Clinical Practice Guideline made several substantive departures from the 2016 edition that warrant a re-examination of contemporary practice. This article reviews the contemporary evidence base across anatomy and pathophysiology, the diagnostic algorithm, conservative management, the resolved and unresolved surgical controversies, complications, and the recurrent-CTS workup. It is intended for surgeons preparing for the examination and for practising hand surgeons looking for a current synthesis. Examination-relevant points are flagged where the syllabus emphasis is highest.
A separate Patient Guide on this site addresses the condition for lay readers, and the Open Carpal Tunnel Release procedure page documents the operative technique and pitfalls in detail.

§ 01 · EPIDEMIOLOGY AND PATHOPHYSIOLOGY

Prevalence and incidence

The foundational prevalence figures from Atroshi's Swedish general-population study remain the most cited: 14.4% of adults report symptoms in the median nerve distribution, 3.8% meet clinical examination criteria, 4.9% have abnormal electrophysiology, and 2.7% are confirmed both clinically and electrodiagnostically.1 The female-to-male ratio sits between 2:1 and 3:1 in contemporary primary-care data, having narrowed over recent decades from the historical 3:1 to 10:1.2 Bilateral involvement is the rule rather than the exception, exceeding 60% in most published series.
Lifetime risk of carpal tunnel release in Finnish registry data approaches 3% of the population.3 Occupational prevalence varies from below 1% to over 60% depending on the job category and the case definition used, with the highest rates in cold-environment manual work — butchers, frozen-food workers, grinders, and poultry processors. The contemporary AAOS consensus position is that high-volume keyboard use is not a major causative factor, despite the persistence of this association in popular literature.4

Risk factors

Quantified associations from contemporary meta-analyses and registry data:
  • Obesity. Body-mass-index-adjusted odds ratio 2.02 for CTS in obese subjects, with each unit BMI increase raising risk by 7.4% (Shiri 2015 Obesity Reviews, 58 studies, ~1.36 million subjects).5
  • Diabetes mellitus. Pooled odds ratio 1.97 (95% CI 1.56–2.49) independent of obesity; CTS may also precede the diagnosis of diabetes by up to 10 years.6
  • Hypothyroidism. Odds ratio approximately 1.4.
  • Pregnancy. Clinical incidence 31–62%, neurophysiologically confirmed in 7–43%; symptoms persist beyond delivery in over 50% at one year and approximately 30% at three years.7
  • Rheumatoid arthritis and hemodialysis-related β2-microglobulin amyloidosis remain established secondary causes.
  • Wild-type transthyretin amyloidosis (ATTRwt). Carpal tunnel syndrome is present in roughly half of patients with cardiac ATTRwt and may precede cardiac disease by 5–10 years. Bilateral CTS in older men should be regarded as a red flag warranting consideration of systemic amyloidosis.8
Examination notes. The Atroshi 1999 prevalence figures (3.8% / 4.9% / 2.7%) and the bilateral CTS / ATTR red flag are the contemporary statistical and clinical pearls that exam questions reach for.

Pathophysiology

The canonical mechanical-compression model remains the dominant framework. Sustained or intermittent elevation of carpal tunnel pressure above the venular threshold of approximately 4 kPa below diastolic pressure — established by Gelberman and Szabo in human and animal studies — causes endoneurial oedema, venous congestion, and ischaemia, which in turn drive segmental demyelination and, with prolonged compression, axonal loss. Lundborg and Dahlin's "miniature compartment syndrome" framing captures the self-perpetuating nature of the cycle: oedema restricts gliding, restricted gliding amplifies compression injury during normal hand motion, and the histological end-state is fibrotic.9
Histopathological work over the last two decades has shifted attention to the (SSCT) as the primary pathological tissue rather than the median nerve itself. The SSCT in idiopathic CTS shows non-inflammatory thickening with vascular proliferation, fibrosis, increased collagen III deposition, and elevated TGF-β receptor expression — a pattern consistent with shear injury rather than primary inflammation.10,11 Animal models (rabbit shear-injury, glucose-injection) reproduce these changes. More recent work has identified higher T-lymphocyte densities in SSCT of CTS patients than in controls, raising the possibility of a neuroimmune component that may eventually inform medical therapy.12
Acute carpal tunnel syndrome — as occurs after distal radius fracture, perilunate dislocation, or compartment syndrome of the forearm — is pathophysiologically distinct: rapid pressure elevation causes acute ischaemia and warrants urgent decompression on different time-scales from the chronic disease.

§ 02 · ANATOMY

The carpal tunnel is a fibro-osseous canal whose floor is the volar surface of the proximal carpal row. Its walls are the tuberosity and radially and the and ulnarly. The roof is the (TCL), the thickened central portion of the , 1.5–3.5 mm in thickness, continuous proximally with the distal antebrachial fascia and distally with the palmar aponeurosis. The tunnel transmits ten structures: nine flexor tendons (four flexor digitorum superficialis, four flexor digitorum profundus, flexor pollicis longus) and the median nerve.

The Lanz classification and its surgical relevance

The Lanz classification of recurrent thenar (motor) branch variation, published in 1977, is the single most-tested anatomical knowledge in FEBHS examination on this topic.13 Four groups are described:
  • Group I — variations in the course of the recurrent motor branch:
- Extraligamentous (the standard textbook course): branch arises distal to the TCL and recurs to enter the thenar musculature. - Subligamentous: branch arises beneath the TCL and curves around its distal edge. - Transligamentous: branch arises beneath the TCL and pierces it directly to reach the thenar musculature — the variant most at risk during release.
  • Group II — accessory thenar branches at the distal aspect of the carpal tunnel.
  • Group III — high division of the median nerve (with or without persistent median artery and/or bifid median nerve).
  • Group IV — accessory thenar branches arising proximal to the carpal tunnel.
Pooled prevalence of Group I subtypes from Henry's 2015 systematic review and meta-analysis covering 3,918 hands: extraligamentous 75.2%, subligamentous 13.5%, transligamentous 11.3%.14 The original Lanz figures (46% / 31% / 23%) reflect a smaller and methodologically different cohort and are now superseded by the meta-analytical pooled data, though both are commonly cited in exam settings.
The transligamentous variant is particularly hazardous during endoscopic release because the blade trajectory passes immediately deep to the TCL where the variant emerges. An ulnar-side take-off of the recurrent motor branch — present in approximately 2.1% of hands — is the highest-risk variant of all and is the principal anatomical reason for entering the carpal tunnel ulnar to the median nerve at open release.

The Berrettini branch

The Berrettini branch is a sensory communicating branch from the common digital nerve of the third web space (ulnar nerve) to the third common digital nerve of the median nerve. Stancić's 1999 cadaveric series of 100 fresh palms remains the reference for the surgical anatomy: superficial palmar communication was present in 81% of dissected hands, and in 28% of all hands the branch lay above the distal edge of the transverse carpal ligament — proximally enough that it is at risk of injury during both endoscopic and mini-open release.15 Kaiser's 2024 cadaveric study of 104 wrists identified the proximally-located Berrettini branch as one of four recurring dangerous anatomical configurations relevant to mini-invasive release.16 The functional consequence of injury is loss of sensation in the third web space, but the patient may report it as a generic "patch of numbness" easily misattributed to the operation itself.

Bifid median nerve and persistent median artery

The bifid median nerve and persistent median artery are recognised variants whose prevalence has been substantially clarified by high-frequency ultrasound. The largest contemporary series (Walker, 1,026 wrists) reports bifid median nerve in 8.6% and persistent median artery in 3.7%, with frequent co-occurrence.17 Higher detection rates are reported with 18-MHz transducers. Neither variant is independently associated with clinical CTS, but a thrombosed or aneurysmally dilated persistent median artery can become symptomatic in its own right and is occasionally identified as the proximate cause of acute or progressive CTS. Pre-operative ultrasound that identifies these variants reduces the iatrogenic risk during all release techniques.

Other surgically relevant anatomy

  • The palmar cutaneous branch of the median nerve arises approximately 5 cm proximal to the wrist crease, runs through or radial to the FCR sheath, and is at risk with proximal extension of the palmar incision; transection produces a tender neuroma at the thenar base.
  • , drawn from the apex of the first web space across the palm parallel to the proximal palmar crease, marks the approximate radial-distal limit of the (6–11 mm distal to the line). Operative dissection should remain proximal to this landmark.
  • The distal antebrachial fascia is continuous with the proximal TCL, and incomplete release of this fascia is the most commonly identified cause of persistent post-operative symptoms.
  • Contents of the carpal tunnel proper, in order from radial to ulnar at the level of the hook of hamate: flexor pollicis longus, the median nerve in the volar-radial quadrant, the flexor digitorum superficialis tendons of the index and long fingers superficially, ring and small fingers more deeply, and the four flexor digitorum profundus tendons in the deepest layer.
Examination notes. The Lanz classification with subtype prevalence, the Berrettini branch with its 81% prevalence and 28% at-risk position, and the safe-zone landmarks (Kaplan's line, distal antebrachial fascia) are all perennial examination material.

§ 03 · CLINICAL DIAGNOSIS

Symptom pattern

The classic presentation combines nocturnal paraesthesia in the median nerve distribution (thumb, index, middle, and radial half of the ring finger), positional provocation of symptoms during sustained wrist flexion or extension (driving, holding a phone, reading), and the "flick sign" — the patient describes shaking the hand to relieve symptoms. Pain may radiate proximally to the forearm and rarely above the elbow; radiation alone does not exclude CTS but should prompt consideration of . Thenar weakness, two-point discrimination loss, and visible thenar atrophy mark advanced disease and are typically late findings.

Provocative tests

The 2023 meta-analysis by Ozdag and colleagues, drawing on 67 studies and 8,924 hands, provides contemporary pooled sensitivities and specificities for the standard provocative tests:18
  • : median sensitivity 0.70 (interquartile range 0.51–0.85), specificity 0.80.
  • : sensitivity 0.67 with variable specificity.
  • : sensitivity 0.45 (95% CI 0.34–0.57), specificity 0.78.
  • Static two-point discrimination: specificity 0.90 (highest specificity among examination findings).
  • Semmes–Weinstein monofilament threshold: specificity 0.85.
The described by Cheng and Mackinnon in 2008 has not held up under independent blinded study; original sensitivity of 0.64 has been replicated at considerably lower values in subsequent series, and the test should not be used as the sole diagnostic instrument.19 Combination tests such as the "Phdurkan" achieve high sensitivity at the cost of specificity and are best understood as screening rather than diagnostic.

CTS-6: the contemporary clinical diagnostic instrument

The CTS-6, derived and validated by Graham and colleagues in 2006, is a six-item weighted clinical scoring instrument combining two history items (nocturnal numbness, numbness in median distribution) and four examination items (thenar atrophy or weakness, positive Phalen, positive Tinel, two-point discrimination loss).20 A score above 12 corresponds to a probability of CTS of approximately 0.80 in the validation cohort. The 2024 AAOS Clinical Practice Guideline endorses CTS-6 as a strong recommendation for diagnosis of carpal tunnel syndrome without routine electrodiagnostic studies or ultrasonography in cases without diagnostic uncertainty.21,22 This is one of the most substantive departures from the 2016 guideline.
CTS-6 is not recommended as the sole diagnostic instrument when the presentation is atypical, when polyneuropathy or cervical radiculopathy is suspected, when severity grading affects surgical planning, or in medico-legal and workers' compensation contexts in which objective severity documentation is required.

Patient-reported outcome measures

The (BCTQ; Levine 1993) remains the dominant outcome measure, comprising the 11-item Symptom Severity Scale (SSS) and the 8-item Functional Status Scale (FSS), each on a 1–5 Likert scale. The minimal clinically important difference for the BCTQ-SSS is conventionally cited as 1.0 to 1.14 points, although Kleermaeker's 2018 work in 180 patients argued that MCID is more correctly proportional to baseline (regression slope 0.46 × baseline SSS).23 Diabetic patients require larger absolute improvement to register as "improved" than non-diabetics — 1.55 SSS in the Ozer 2013 series compared with 1.45 in non-diabetic patients.24
The Atroshi–Lyrén 6-item symptom scale, derived by item-response theory from the BCTQ-SSS, has demonstrated better responsiveness (effect size 2.02 versus 1.59 for BCTQ-SSS) and shorter administration time, and is increasingly preferred in contemporary research settings.25
QuickDASH provides upper-limb regional functional measurement and is used as a generic comparator across hand conditions rather than as a CTS-specific instrument.

Differential diagnosis

The differential includes cervical radiculopathy (C6 or C7), , thoracic outlet syndrome, double crush, diabetic and small-fibre polyneuropathy, Parsonage–Turner syndrome (often anterior interosseous nerve), and trapeziometacarpal arthritis with overlapping pain pattern. The diagnostic discipline is to identify the dominant pattern rather than attempt to exclude every alternative; in the typical CTS presentation the differential is narrow and CTS-6 is decisive, while in atypical presentations the differential expands and electrodiagnostic studies and imaging become essential.
Examination notes. CTS-6 strong endorsement by AAOS 2024; the BCTQ MCID controversy; Phalen and Durkan sensitivity-specificity figures; the scratch collapse test reliability problem.

§ 04 · ELECTRODIAGNOSTIC STUDIES

The role of electrodiagnostic studies has shifted from a routine confirmatory test to a selectively-used severity and differential instrument. The AAEM/AAN/AAPMR practice parameter remains the procedural reference: median sensory conduction across the wrist over a 14-cm segment, with comparative testing (median–ulnar, median–radial, palm–wrist) where the absolute latencies are normal but clinical suspicion remains high.26 Comparative tests have sensitivity of approximately 85%, exceeding standard absolute latency measurements.

Severity grading

Two grading systems remain in widespread use:
  • Padua classification (1997) — six categories: Negative, Minimal (only on comparative tests), Mild (abnormal sensory conduction velocity, normal distal motor latency), Moderate (abnormal SCV and DML), Severe (absent sensory nerve action potential with abnormal DML), Extreme (absent SNAP and absent compound muscle action potential).27
  • Bland scale (2000) — grades 0 to 6, more granular but with classification overlap when applied to large datasets.
Both systems remain in current use and the choice between them is largely institutional.

False negatives and clinical concordance

Approximately 10–25% of clinically definite CTS shows normal nerve conduction studies, depending on series and case definition. Causes include small-fibre-predominant disease, intermittent symptoms at the time of testing, technical factors, and a cool limb. The 2024 AAOS guideline's strong endorsement of CTS-6 reflects the recognition that requiring electrophysiological confirmation in every case introduces meaningful diagnostic delay without changing management in the typical presentation.

Where electrodiagnostic studies remain indicated

  • Atypical clinical presentation.
  • Suspected polyneuropathy, cervical radiculopathy, or proximal compression.
  • Severity grading that will alter the surgical decision (for example, the patient considering a delay-of-surgery trial of injection in the presence of severe denervation findings).
  • Pre-operative documentation in medico-legal or workers' compensation contexts.
  • Evaluation of the recurrent or persistent post-operative case.
Examination notes. The Padua classification thresholds, the AAEM/AAN/AAPMR comparative-testing protocol, and the 10–25% false-negative figure are commonly examined.

§ 05 · NEUROMUSCULAR ULTRASOUND

of the median nerve has matured from an adjunct to a co-primary diagnostic modality over the last decade. Diagnostic accuracy is now well-characterised across multiple meta-analyses.

Diagnostic thresholds

The standard parameter is median nerve cross-sectional area (CSA) at the carpal tunnel inlet at the level of the pisiform. The most widely used threshold is 9 mm2, with some authorities preferring 10 mm2. Tai's 2012 meta-analysis (28 studies, 3,995 wrists) established a diagnostic odds ratio of 40.4 for CSA ≥9 mm2 with pooled sensitivity 87.3% and specificity 83.3%.28 Miller's 2024 paired-accuracy meta-analysis demonstrated that neuromuscular ultrasound and electrodiagnostic studies have broadly equivalent accuracy: pooled sensitivity 86.4% versus 91.6%, specificity 79.3% versus 81.9% respectively.29
Adjunct measurements that can refine accuracy:
  • The wrist-to-forearm ratio (WFR), abnormal at >1.4.
  • The ΔCSA (carpal tunnel inlet minus mid-forearm), abnormal at >2 mm2.
  • Body-surface-area-adjusted CSA, which improves accuracy in extreme habitus (Roll 2023).30
  • Decreased longitudinal nerve sliding on dynamic ultrasound and increased intraneural flow on power Doppler in active disease.

Beyond static measurement

Ultrasound complements rather than competes with electrodiagnostic studies because it answers a different question. Electrodiagnostic studies measure how the nerve is working; ultrasound shows what the nerve looks like. In addition to the diagnostic question, ultrasound usefully:
  • Identifies anatomical variants pre-operatively (bifid nerve, persistent median artery, accessory branches).
  • Identifies secondary causes (ganglion, lipoma, persistent median artery thrombosis, tenosynovitis, amyloid deposits within the flexor tendons in ATTR).
  • Supports guided injection — discussed in § 06.
  • Forms the diagnostic platform for ultrasound-guided percutaneous release — discussed in § 07.
The 2022 expert consensus statement of Pelosi and colleagues in Clinical Neurophysiology recommends combined electrodiagnostic and ultrasound evaluation in equivocal cases as the contemporary standard of care, rather than choosing between them.31

§ 06 · CONSERVATIVE MANAGEMENT

Splinting

The 2023 update of the Cochrane review on splinting (Karjalainen et al.) found low-certainty evidence that night splints worn for at least four weeks more than triple short-term overall improvement compared with no treatment (relative risk 3.86), with a BCTQ-SSS difference of 0.37 points — below the conventional MCID.32 No splint design or wearing regimen was demonstrably superior to others. Effectiveness diminishes with severity, and severe disease should not be managed with splinting alone.

Corticosteroid injection

Atroshi's 2013 randomised trial in Annals of Internal Medicine compared 80 mg methylprednisolone, 40 mg methylprednisolone, and placebo at 10 weeks: both active doses outperformed placebo at 10 weeks with a dose-response gradient, but the surgery rate at one year was approximately 75% across all three arms.33 The 2021 JAMA Network Open extended five-year follow-up showed no symptom-severity difference between groups and a modest delay-of-surgery effect in the 80 mg arm only.34
The INSTINCTS trial (Chesterton 2018, Lancet) compared single 20 mg methylprednisolone injection with night splinting in primary care: injection was superior at 6 weeks with no difference at 6 months.35 Ly-Pen and colleagues demonstrated surgery superior to single injection at 2 years.36 The 2024 AAOS guideline gives a strong recommendation that corticosteroid injection does not provide long-term benefit.21
The evidence base for ultrasound-guided versus blind injection is now substantial. Wu's 2024 meta-analysis covering eight studies showed that ultrasound-guided injection produces lower BCTQ-SSS scores (weighted mean difference −0.50), lower complication rates (relative risk 0.58), and lower subsequent need for surgery (relative risk 0.55) than landmark-based injection.37 The risks of blind injection — intraneural injection causing thenar wasting or persistent dysaesthesia, fat necrosis, dermal atrophy — are sufficient that ultrasound guidance should be regarded as the contemporary standard.

Other agents and modalities

  • Oral corticosteroids: short-term benefit at two to four weeks; no long-term evidence (Hui & Wong 2001).
  • NSAIDs, vitamin B6, diuretics: insufficient or no evidence for symptom modification (O'Connor Cochrane).
  • Platelet-rich plasma: AAOS 2024 strong recommendation against — no long-term benefit demonstrated.21
  • Therapeutic ultrasound: AAOS 2024 — no long-term benefit.
  • Acupuncture and low-level laser: insufficient Cochrane evidence (Choi 2018, Rankin 2017).
  • Nerve and tendon gliding exercises: limited evidence for stand-alone benefit; combined with night splinting may help mild CTS (Abdolrazaghi 2023).
  • Manual therapy: short-term equivalence to surgery in mild-to-moderate CTS at one month in Fernández-de-Las-Peñas trials, with surgery superior at longer follow-up.
  • Yoga: modest benefit in Garfinkel 1998.
  • Workstation modification: insufficient evidence (O'Connor Cochrane); AAOS 2024 — no association established between high keyboard use and CTS.
Examination notes. AAOS 2024 strong recommendations in conservative management: against PRP, against long-term steroid benefit, against therapeutic ultrasound. The Atroshi 2013 Ann Intern Med dose-response and 2021 JAMA Netw Open extended follow-up are landmark references.

§ 07 · SURGICAL TREATMENT

Open carpal tunnel release

Open carpal tunnel release through a 2–3 cm palmar incision aligned with the radial border of the ring finger ray, ulnar to the thenar crease and stopping well proximal to Kaplan's cardinal line, is the contemporary baseline operation. Mini-incision (1.5–2 cm) variants described by Lee and Bromley have demonstrated equivalent symptom relief and modestly lower pillar pain at long-term follow-up.38 The technical detail of the operation is documented in the Open Carpal Tunnel Release procedure page on this site, including pitfall callouts on incision plane, ulnar-side TCL entry, and complete proximal release.

Endoscopic carpal tunnel release

Endoscopic carpal tunnel release was developed in two principal forms — single-portal (Agee, 1992) and two-portal (Chow, 1989) — with subsequent technique refinements. The Vasiliadis 2014 Cochrane review of 28 randomised controlled trials established broadly equivalent symptom relief, with endoscopic release demonstrating less scar tenderness and earlier return to work, balanced against a higher rate of reversible nerve injuries and a meaningful learning curve.39 Major (permanent) nerve injury rates are similar between techniques.
The 11–16-year follow-up of the Atroshi 1998–2002 randomised cohort, published in JAMA in 2015, established equivalent long-term symptom severity and reoperation rates between open and endoscopic release.40 This is the most decisive single piece of evidence on the long-term equivalence question. The 2024 AAOS guideline records a strong recommendation that mini-open and endoscopic release produce equivalent patient-reported outcomes at long-term follow-up.21 Practical short-term differences (return to work approximately five to seven days earlier with endoscopic, less scar tenderness) remain real and are appropriately discussed at consent.
A separate page on endoscopic release will treat the technique in operative detail; the present article restricts itself to the comparative-evidence framing.

Ultrasound-guided percutaneous carpal tunnel release

(USCTR / UCTR) has emerged from a decade of investigational use into clinical adoption in selected centres. Petrover's 2017 series in the Journal of Vascular and Interventional Radiology — 129 hands with MRI-confirmed complete TCL section and no complications — is the seminal reference.41 Sono-instruments (Moungondo 2024 Cureus) and thread-based release (TCTR; Kim 2024 Journal of Clinical Medicine) have produced sustained outcomes equivalent to mini-open at one to five years in selected severity grades.42,43 Recent comparative studies (Hebbard 2024; MDPI 2025, 172 patients) show equivalent functional outcomes with faster return to work.44
The contemporary position is that USCTR is a reasonable option in centres with the equipment, training, and case volume to maintain the technique safely. It is not yet a first-line replacement for open or endoscopic release. The learning curve is real and the absence of large randomised trials against both alternatives is a genuine evidence gap. The 2024 AAOS guideline acknowledges USCTR but does not endorse it over standard techniques.

Internal neurolysis, epineurotomy, and tenosynovectomy

Mackinnon's 1991 randomised trial of 30 versus 31 hands established that internal neurolysis adds no benefit in primary CTS;45 Holmgren-Larsson 1985 and Lowry & Follender 1988 reached the same conclusion in their respective cohorts. The contemporary consensus, endorsed by AAOS, is that these adjunctive procedures should not be performed routinely. Indications for adjunctive flexor tenosynovectomy remain rheumatoid synovitis, dialysis-related amyloidosis, and identifiable mass lesions found at the time of surgery.

Anaesthesia and setting

The wide-awake local anaesthesia no tourniquet (WALANT) approach popularised by Lalonde — 1% lidocaine with 1:100,000 epinephrine, with or without sodium bicarbonate buffering, allowing 25–30 minutes of dwell time before incision — has been adopted at considerable scale.46 It achieves a bloodless field through vasoconstriction without tourniquet, allows intraoperative active testing of the patient, and reduces facility costs by approximately 70–85% per case in published cost analyses. The AAOS 2024 guideline records a strong recommendation for the use of local anaesthesia alone as an acceptable approach.21
Office-based release in a procedure-room setting with field sterility — rather than full theatre sterility — has demonstrated equivalent surgical site infection rates in large series. LeBlanc and colleagues' 1,504-case prospective study reported 0.4% superficial and 0% deep infection without prophylactic antibiotics.47 The 2024 AAOS guideline records limited evidence supporting safe office-based release. The combined trajectory of WALANT and office-based release is the most clinically actionable contemporary shift in carpal tunnel surgery.
Examination notes. AAOS 2024 strong recommendations: long-term equivalence of mini-open and endoscopic release; local anaesthesia alone; NSAIDs/paracetamol post-op. Atroshi 2015 JAMA 11–16-year follow-up. Vasiliadis 2014 Cochrane. Mackinnon 1991 internal neurolysis trial. LeBlanc field-sterility infection data.

§ 08 · POSTOPERATIVE MANAGEMENT

The 2024 AAOS guideline records moderate evidence against routine post-operative immobilisation in a sling, splint, or brace, on the basis that uncomplicated patients recover function more rapidly without it.21 It records moderate evidence against routine supervised hand therapy after uncomplicated open release. Strong evidence supports the combination of a non-steroidal anti-inflammatory drug with paracetamol for post-operative analgesia.
Substantial practice variation persists despite this evidence — von Bergen's 2023 ASSH survey demonstrated that surgeon recommendation drives 99.5% of return-to-work decisions, regardless of the published evidence base.48 The reasoning offered for routine therapy referral typically centres on the value of an early structured consultation in setting realistic expectations, identifying the minority of patients with developing pillar pain or stiffness, and supporting return-to-work conversations — particularly for manual workers. The honest reading of the evidence is that it does not support routine therapy, but that selected indications remain defensible.

Wound and recovery considerations

Wu and colleagues' 2023 randomised trial in the Journal of Hand Surgery (European Volume) compared 4-0 Monocryl subcuticular closure with 4-0 nylon interrupted closure: Monocryl closure produced better Patient and Observer Scar Assessment Scale scores at two weeks, with no difference at six weeks.49 The choice of suture is therefore a surgeon-preference decision within an equivalent long-term evidence base.
Return to work timing has been characterised by Miller and Chung's 2023 systematic review and meta-analysis of 7,386 patients: mean return to activity 13.1 days, with mean return to work differing by surgical technique — mini-open 8.9 days, endoscopic 10.5 days, standard open 17.4 days.50 Predictors of delayed return include manual occupational demand, workers' compensation status, psychological factors (catastrophising, anxiety), and persistent symptoms.

§ 09 · COMPLICATIONS

Major complications of carpal tunnel release sit below 1% in large series. The contemporary figures of substance:
  • Major nerve injury (median or ulnar): 0.11% in open release, 0.13% in endoscopic release (combined, Shields 2023).51 Permanent in 0.2–0.3% across both techniques in published meta-analyses.52
  • Recurrent motor branch injury: rare but functionally significant; risk increased with the transligamentous Lanz variant. The principal preventive measure is ulnar-side entry into the tunnel.
  • Palmar cutaneous branch injury: produces a tender neuroma at the thenar base; minimised by an in-line incision ulnar to the thenar crease and a proximal limit distal to the wrist crease.
  • Superficial palmar arch injury: rare; usually associated with distal endoscopic blade misplacement or inappropriately distal open dissection.
  • Pillar pain: 13–49% incidence depending on definition and method of assessment; the contemporary best estimate from systematic reviews is approximately 13% at 12 weeks, declining to approximately 7% at 18 months.53 Theories include ligamentous biomechanical alteration, neurogenic small-fibre injury, inflammatory and oedematous mechanisms; none has emerged as dominant. Rellan's 2024 prospective WALANT cohort of 170 patients reported 49% incidence with median visual analogue scale score 3 and median three-month duration; psychological correlates (catastrophising, anxiety, depression) were not predictive.54
  • Scar tenderness: more common with standard open release than with mini-incision or endoscopic; mostly resolves by six months.
  • Wound complications: superficial surgical site infection 0.4%, deep infection essentially absent in field-sterility series.47
  • Complex regional pain syndrome: incidence below 1%; predisposing factors include female sex and previous CRPS in another limb.
  • Bowstringing of flexor tendons: a historical concern with complete TCL division. Modern evidence shows minimal functional consequence and most surgeons no longer reconstruct the ligament.

§ 10 · RECURRENT AND PERSISTENT CARPAL TUNNEL SYNDROME

Definitions

The Mackinnon and Pripotnev 2022 framework, published in the Journal of Clinical Medicine, is the contemporary reference for definitions:55
  • Persistent CTS: symptoms never resolved after the index operation.
  • Recurrent CTS: symptom-free interval of at least three months followed by return of symptoms.
  • New CTS: previously asymptomatic territory now symptomatic — for example, contralateral disease developing post-index.
These distinctions matter because the differential diagnosis and the operative approach differ.

Incidence and causes

Long-term reoperation rates across the literature range from 3% to 25%; the Atroshi 2015 cohort reported approximately 12% at 13 years.40 The most common identifiable cause is incomplete proximal release — typically failure to release the distal antebrachial fascia, which is continuous with the proximal TCL. Perineural fibrosis is identified at revision in approximately 88% of cases. Other causes include missed Lanz variant injury, double crush phenomenon, alternative pathology (cervical, pronator syndrome, polyneuropathy), and primary misdiagnosis at the index operation.

Workup

Repeat clinical assessment using CTS-6 against the post-operative baseline is the diagnostic anchor. Electrodiagnostic studies confirm or exclude alternative diagnoses and document severity. Ultrasound is particularly useful in the recurrent setting because it identifies persistent compression sites, perineural fibrosis, and incomplete proximal release directly. Magnetic resonance imaging is reserved for masses or extensive scarring that ultrasound cannot adequately characterise.

Revision options

  • Re-exploration with open neurolysis is the workhorse operation, performed through the original scar and extended proximally to reach un-released distal antebrachial fascia.
  • Hypothenar fat pad flap (Strickland 1996; Mathoulin) interposes vascularised fat between the median nerve and the overlying scar to prevent re-adhesion. Akrivos's 2025 ten-year follow-up in the Journal of Hand Surgery (European Volume) found equivalent visual analogue scale, DN4, and QuickDASH outcomes between open decompression with and without hypothenar fat pad flap.56 The 2024 systematic review by de Roo and colleagues did not demonstrate superiority of the flap over open decompression alone.57
  • Synovial flap, abductor digiti minimi flap, palmaris brevis flap — all described, all with limited comparative evidence.
  • Vein wrap, allograft conduit wrap, collagen wrap — adjuncts in heavily scarred fields.
  • Pedicled or free fat grafts — alternatives to local fat pad rotation.
  • Nerve transfer (anterior interosseous nerve to motor branch) — rarely indicated, reserved for severe established motor loss.
Outcomes of revision surgery are inferior to primary release across all techniques, but most patients achieve symptomatic improvement. Pripotnev and Mackinnon's framework — diagnose precisely, then operate to address the diagnosed cause — remains the operative discipline.
Examination notes. Mackinnon and Pripotnev definitions; the incomplete-release-as-leading-cause finding; the hypothenar fat pad flap controversy.

§ 11 · SPECIAL POPULATIONS

Each of the following groups merits a separate dedicated article; they are flagged here only at the depth required for the contemporary differential and the principles that govern management.
  • Pregnancy-associated CTS: clinical incidence 31–62% (Padua 2010); conservative management is the priority and surgery during pregnancy is rarely required. Approximately half of cases persist at one year and 30% at three years, so post-partum follow-up and reassessment are appropriate.7
  • Diabetic CTS: roughly twice the prevalence of the non-diabetic population; outcomes after release are similar, but the BCTQ-SSS MCID is larger, requiring greater absolute symptom change to register as improved (Ozer 2013).24
  • Hemodialysis-related CTS / β2-microglobulin amyloidosis: associated with chronic dialysis exceeding five years, frequently bilateral, often aggressive in symptom progression; surgery is commonly required and the operative findings include amyloid deposition within the flexor tenosynovium.
  • Wild-type ATTR amyloidosis: bilateral CTS in older men should prompt consideration of systemic amyloidosis and cardiac evaluation; CTS may precede the cardiac diagnosis by 5–10 years.8
  • Bilateral simultaneous release: feasible with WALANT; modest evidence supports patient preference and similar outcomes to staged surgery.
  • Paediatric CTS: rare; consider mucopolysaccharidoses (Hurler, Hunter syndromes), congenital disorders.
  • Athletes and musicians: anecdotal management; aim for early diagnosis and minimally disruptive treatment.

§ 12 · CONTEMPORARY DEBATES

The unresolved or partially-resolved questions:
  • Open versus endoscopic release: long-term equivalence is now the AAOS-endorsed position. Short-term differences (faster return to work and less scar tenderness with endoscopic, balanced against higher transient nerve dysfunction) remain real and should be discussed at consent. The choice is surgeon- and system-dependent without superiority claim.
  • USCTR: promising evidence base but lacking large randomised trials versus both open and endoscopic. Reasonable in centres with the equipment, training, and case volume; not yet first-line outside specialised practice.
  • WALANT versus traditional anaesthesia: strong evidence for local-only; adoption barriers are theatre culture, reimbursement structure, and training rather than evidence.
  • Office-based versus operating room: cost reduction substantial, infection rates equivalent in field-sterility series, AAOS limited evidence supportive. The combined WALANT-and-office-based shift is the contemporary direction of travel.
  • Routine post-operative hand therapy: practice variation persists despite moderate evidence against routine prescription. The defensible position is that selected indications remain reasonable but routine referral is not evidence-based.
  • Diagnostic algorithm: clinical-only (CTS-6) versus always-NCS versus ultrasound-first — three competing schools. CTS-6 is the AAOS-endorsed default for typical presentations; electrodiagnostic studies for atypical or severity-defining cases; ultrasound increasingly co-primary, particularly for variant detection and ATTR red-flag workup.
  • Bilateral CTS in older men as ATTR red flag: increasing recognition; the article's clinical pearl.

§ 13 · SUMMARY POSITIONS

The contemporary defensible positions:
  1. Diagnose carpal tunnel syndrome clinically using CTS-6 in typical presentations; reserve electrodiagnostic studies and high-resolution ultrasound for atypical, severe, or operatively-defining cases. Ultrasound is co-primary, not subordinate, to electrodiagnostic studies.
  2. Treat conservatively with night splinting in mild and moderate disease; discuss corticosteroid injection as a delaying rather than definitive intervention; perform any injection under ultrasound guidance; do not offer platelet-rich plasma.
  3. Operate by open or endoscopic release as preferred and indicated; expect equivalent long-term outcomes, modest short-term differences favouring endoscopic; consider USCTR in appropriately resourced practice.
  4. Use local anaesthesia alone as the default; consider office-based release; do not perform routine internal neurolysis, epineurotomy, or tenosynovectomy in primary CTS.
  5. After uncomplicated release, do not splint routinely and do not refer routinely to supervised hand therapy; selected indications remain defensible. Use NSAIDs with paracetamol for post-operative analgesia.
  6. In the recurrent or persistent case, diagnose precisely (history, examination, electrodiagnostic studies, ultrasound, MRI when indicated) and operate to address the diagnosed cause — most commonly incomplete proximal release. The hypothenar fat pad flap has not demonstrated superiority over re-exploration with open neurolysis alone.
  7. Recognise bilateral CTS in older men as a possible early manifestation of wild-type transthyretin amyloidosis.